多重用药与老年人衰弱风险升高相关:一项8年纵向队列研究
该研究纳入4402名基线无衰弱的高危或膝骨关节炎北美个体,随访8年,共361人发生衰弱。调整11项基线混杂因素后,使用4-6种药物者衰弱风险升高55%,使用≥7种药物者升高约147%,基线每增加一种药物衰弱风险增加11%,呈剂量反应关系。
要点
- 使用4-6种药物者衰弱风险较0-3种者升高55%(HR=1.55)。
- 使用≥7种药物者衰弱风险升高约147%(HR=2.47)。
- 基线每增加一种药物,随访衰弱风险增加11%(HR=1.11)。
核心结论
- 多重用药与8年随访期间衰弱发生率升高相关,且呈剂量反应关系。
研究设计与样本
- 纵向队列研究,随访8年,纳入4402名基线无衰弱的高危或膝骨关节炎个体。
主要发现
- 8年随访中4402名基线参与者有361人发生衰弱。
- 与使用0-3种药物者相比,使用4-6种药物者衰弱发生率约翻倍,使用≥7种药物者约高6倍。
- 调整11项基线混杂因素后,使用4-6种药物者衰弱风险升高55%(HR=1.55;95%CI 1.22-1.96;P<.0001)。
- 使用≥7种药物者衰弱风险升高约147%(HR=2.47;95%CI 1.78-3.43;P<.0001)。
- 基线每增加一种药物,随访时衰弱风险增加11%(HR=1.11;95%CI 1.07-1.15;P<.0001)。
关键数值与推荐
- 药物处方按0-3种、4-6种、≥7种分类。
- 衰弱采用骨质疏松性骨折研究指数定义:基线至后续随访体重下降≥5%、无法完成5次坐立、按该指数定义的低能量水平,三项中≥2项。
临床怎么用
- 对老年患者应关注多重用药与衰弱风险的关联,尤其使用4种及以上药物者。
- 在临床评估中可将用药数量作为衰弱风险的参考信息之一。
局限性
- 原文指出未来需进一步研究确认该发现并探索潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether polypharmacy is associated with a higher incidence of frailty in a large cohort of North Americans during 8 years of follow-up. DESIGN: Longitudinal study, follow-up of 8 years. PARTICIPANTS: A total of 4402 individuals at high risk or having knee osteoarthritis free from frailty at baseline. MEASUREMENTS: Details regarding medication prescription were captured and categorized as 0-3, 4-6, and ≥7. Frailty was defined using the Study of Osteoporotic Fracture index as the presence of ≥2 out of (1) weight loss ≥5% between baseline and the subsequent follow-up visit; (2) inability to do 5 chair stands; and (3) low energy level according to the Study of Osteoporotic Fracture definition. Cox's regression models calculating a hazard ratio (HR) with 95% confidence intervals (CIs), adjusted for potential confounders, were undertaken. RESULTS: During the 8-year follow-up, from 4402 participants at baseline, 361 became frail. Compared with participants taking 0-3 medications, the incidence of frailty was approximately double in those taking 4-6 medications and 6 times higher in people taking ≥7 medications. After adjusting for 11 potential baseline confounders, participants using 4-6 medications had a higher risk of frailty of 55% (HR = 1.55; 95% CI 1.22-1.96; P < .0001), whereas those using more than 7 drugs were at approximately 147% (HR = 2.47; 95% CI 1.78-3.43; P < .0001). Each additional drug used at the baseline increased the risk of frailty at the follow-up of 11% (HR = 1.11; 95% CI 1.07-1.15; P < .0001). CONCLUSIONS: Polypharmacy is associated with a higher incidence of frailty over 8-year follow-up period. Our data suggest evidence of a dose response relationship. Future research is required to confirm our findings and explore underlying mechanisms.
引用
- Veronese N, Stubbs B, Noale M, et al. Polypharmacy Is Associated With Higher Frailty Risk in Older People: An 8-Year Longitudinal Cohort Study. J Am Med Dir Assoc. 2017. PMID: 28396180. doi:10.1016/j.jamda.2017.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。